Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment
Protein Science · 2026
DOI: 10.1002/pro.70444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2026. Verfasst von Annalisa Pia Abbinantefina und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Ro…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Organoids, Pancreatic Neoplasms, Ferritins. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Next Generation EU, MUR. PRIN 2022, NextGenerationEU.
Abstract (Originalsprache)
Activating KRAS mutations, particularly G12 variants, are key drivers in pancreatic ductal adenocarcinoma and other cancers. While KRAS was historically considered undruggable, mutant‐specific inhibitors, including non‐covalent KRAS G12D inhibitor MRTX1133, have emerged. However, efficacy and resistance remain challenges. We utilized a stimuli‐sensitive, ferritin‐derived nanomedicine platform to encapsulate high concentrations of MRTX1133, aiming for targeted delivery of the drug to KRAS‐mutated pancreatic ductal adenocarcinoma cells. This platform, designed for enhanced biodistribution and reduced off‐target effects, achieved a major efficacy over free MRTX1133 in 2D models regarding cell proliferation and KRAS inhibition pathway and, in 3D spheroid models, specifically concerning cell death. Efficacy in patient‐derived organoids was comparable. This study demonstrates the potential of this nanomedicine platform for targeted delivery of KRAS mutant‐specific inhibitors to human tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy.
- Institute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
- Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome, Italy.
- GSTeP Organoids Research Core Facility, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
- Department of Wellbeing, Health and Environmental Sustainability (BeSSA), Sapienza University of Rome, Rieti, c/o Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical…
ORCID-Profile: Francesco Fazi
Förderung
- Next Generation EU
- MUR. PRIN 2022
- NextGenerationEU
Zitieren
APA
Abbinantefina, A. P., Tito, C., Masciarelli, S., Tisci, G., Ceci, P., Falvo, E., Ruta, V., Panzeri, V., Sette, C., Fazi, F., & Colotti, G. (2026). Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment. Protein Science. https://doi.org/10.1002/pro.70444
Vancouver
Abbinantefina AP, Tito C, Masciarelli S, Tisci G, Ceci P, Falvo E, et al. Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment. Protein Science. 2026. doi:10.1002/pro.70444
BibTeX
@article{Abbinantefina2026,
author = {Abbinantefina, Annalisa Pia and Tito, Claudia and Masciarelli, Silvia and Tisci, Giada and Ceci, Pierpaolo and Falvo, Elisabetta and Ruta, Veronica and Panzeri, Valentina and Sette, Claudio and Fazi, Francesco and Colotti, Gianni},
title = {Ferritin‐based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient‐derived organoids: A novel approach for treatment},
journal = {Protein Science},
year = {2026},
doi = {10.1002/pro.70444}
}
EUVIMED